Thomas Leonard
Directeur/Bestuurslid bij NUGENEREX IMMUNO-ONCOLOGY, INC.
Actieve functies van Thomas Leonard
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| NUGENEREX IMMUNO-ONCOLOGY, INC. | Directeur/Bestuurslid | - | - |
| Independent Dir/Board Member | - | - |
Loopbaan van Thomas Leonard
Eerdere bekende functies van Thomas Leonard
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Opleiding van Thomas Leonard
| New York University | Graduate Degree |
| St. John's University | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
Operationeel
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
NuGenerex Immuno-Oncology, Inc.
 NuGenerex Immuno-Oncology, Inc. BiotechnologyHealth Technology NuGenerex Immuno-Oncology, Inc. is an oncology company focuses on the modulation of the immune system to treat cancer. It develops immunotherapeutic products and vaccines based on proprietary, patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) class II associated invariant chain that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The company was founded on October 8, 1993 and is headquartered in Miramar, FL. | Health Technology |
- Beurs
- Insiders
- Thomas Leonard
- Ervaring
